R Angelo de Claro Selected Research

ponatinib

1/2022

FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

R Angelo de Claro Research Topics

Disease

4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2023 - 01/2020
3	Neoplasms (Cancer) 01/2023 - 12/2020
3	Fatigue 01/2022 - 01/2017
2	Hyperlipidemias (Hyperlipidemia) 01/2022 - 06/2011
2	Respiratory Tract Infections (Respiratory Tract Infection) 12/2019 - 01/2017
2	Diarrhea 12/2019 - 01/2017
2	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2019 - 01/2017
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019 - 02/2011
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2019 - 11/2012
2	Hodgkin Disease (Hodgkin's Disease) 01/2017 - 11/2012
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 08/2015 - 04/2015
1	Rare Diseases (Rare Disease) 12/2023
1	Leukemia 01/2023
1	Hypertension (High Blood Pressure) 01/2022
1	Liver Diseases (Liver Disease) 01/2022
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2022
1	Pancreatitis 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Acute Promyelocytic Leukemia 11/2020
1	Second Primary Neoplasms (Neoplasms, Second) 11/2020
1	Mycosis Fungoides 12/2019
1	Infections 12/2019
1	Musculoskeletal Pain 12/2019
1	Exanthema (Rash) 12/2019
1	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2019
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2019
1	Fever (Fevers) 01/2017
1	Cough 01/2017
1	Cytopenia 01/2017
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 08/2015
1	Lymphoma (Lymphomas) 04/2015
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 04/2015
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/2015
1	Inflammation (Inflammations) 06/2011
1	Atherosclerosis 06/2011
1	Sepsis (Septicemia) 02/2011

Drug/Important Bio-Agent (IBA)

3	Brentuximab VedotinIBA 01/2019 - 11/2012
2	Azacitidine (5 Azacytidine)FDA Link 11/2023 - 01/2022
2	ivosidenibIBA 11/2023 - 01/2020
2	TabletsIBA 01/2022 - 04/2015
2	NivolumabIBA 01/2021 - 01/2017
1	Tyrosine Kinase InhibitorsIBA 01/2023
1	cedazuridineIBA 01/2022
1	cc-486IBA 01/2022
1	decitabine and cedazuridine drug combinationIBA 01/2022
1	ponatinibIBA 01/2022
1	Decitabine FDA Link 01/2022
1	Cytidine DeaminaseIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	PlatinumIBA 01/2021
1	Anaplastic Lymphoma KinaseIBA 01/2021
1	IpilimumabIBA 01/2021
1	Arsenic Trioxide (Trisenox)FDA Link 11/2020
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2020
1	enasidenibIBA 01/2020
1	mogamulizumabIBA 12/2019
1	SteroidsIBA 12/2019
1	CCR ReceptorsIBA 12/2019
1	Prednisone (Sone)FDA LinkGeneric 01/2019
1	axicabtagene ciloleucelIBA 01/2019
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019
1	Chimeric Antigen ReceptorsIBA 01/2019
1	Transaminases (Aminotransferases)IBA 01/2017
1	ibrutinibIBA 08/2015
1	idelalisibIBA 04/2015
1	Interleukin-10 (Interleukin 10)IBA 06/2011
1	LDL Receptors (LDL Receptor)IBA 06/2011
1	Interleukin-12 (IL 12)IBA 06/2011
1	Interleukin-6 (Interleukin 6)IBA 06/2011
1	Fas Ligand Protein (Fas Ligand)IBA 06/2011
1	Proteins (Proteins, Gene)FDA Link 02/2011

Therapy/Procedure

8	Therapeutics 01/2023 - 04/2015
3	Drug Therapy (Chemotherapy) 10/2022 - 11/2012
2	Hematopoietic Stem Cell Transplantation 12/2019 - 01/2017
1	Immunotherapy 12/2023
1	Induction Chemotherapy 01/2022
1	Transplantation 01/2017
1	Stem Cell Transplantation 11/2012
1	Ligation 02/2011
1	Punctures 02/2011